ANTX: AN2 Therapeutics Forward P/S Multiple

Public company logo of AN2 Therapeutics Inc (ANTX)

The narrow specialization of AN2 Therapeutics, Inc. (ANTX) in treating rare pulmonary pathologies creates high binary risks. However, the integration of new antibiotics into medical protocols establishes a critical therapeutic hub. The expected market cap-to-revenue ratio on the GURU.Markets chart demonstrates market expectations, where determines the current status of the parameter. This accompanies the pipeline expansion strategy and the commercial market launch of epetraronal.

ANTX AN2 Therapeutics Inc: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/17/2026

Analytical breakdowns for AN2 Therapeutics, Inc.

- stock price and consensus target price:
Fundamental company analysis:ANTX (AN2 Therapeutics Inc)
Original product of an2therapeutics.com

To identify fundamental benchmarks in the financial statements of AN2 Therapeutics, Inc. (ANTX), investors utilize the ratio of market capitalization to projected revenue. The projected P/S value on the GURU.Markets platform is calculated based on current sales forecasts and the current share price, reflecting market expectations for the commercialization of epitebrorol in the rare infections segment, where sharp fluctuations in the chart signal either a revaluation of R&D potential or a fair increase in business value.